Erasca to Present at Upcoming Investor Conferences
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announces its participation in three upcoming investor conferences. The company will present at the Guggenheim Securities Healthcare Innovation Conference in Boston (November 12), the Jefferies London Healthcare Conference (November 20), and the 7th Annual Evercore HealthCONx Conference in Coral Gables (December 4). Management will engage in one-on-one investor meetings, and live audio webcasts will be available on Erasca.com/events, with replays accessible for 90 days.
Erasca (Nasdaq: ERAS), un'azienda di oncologia di precisione in fase clinica focalizzata sui tumori guidati dalla via RAS/MAPK, annuncia la sua partecipazione a tre imminenti conferenze per investitori. L'azienda presenterà alla Guggenheim Securities Healthcare Innovation Conference a Boston (12 novembre), alla Jefferies London Healthcare Conference (20 novembre) e alla 7th Annual Evercore HealthCONx Conference a Coral Gables (4 dicembre). La direzione parteciperà a incontri one-to-one con gli investitori e saranno disponibili webcast audio dal vivo su Erasca.com/events, con replay accessibili per 90 giorni.
Erasca (Nasdaq: ERAS), una empresa de oncología de precisión en etapa clínica centrada en los cánceres impulsados por la vía RAS/MAPK, anuncia su participación en tres próximas conferencias para inversores. La empresa presentará en la Guggenheim Securities Healthcare Innovation Conference en Boston (12 de noviembre), en la Jefferies London Healthcare Conference (20 de noviembre) y en la 7th Annual Evercore HealthCONx Conference en Coral Gables (4 de diciembre). La dirección participará en reuniones individuales con inversores y se realizarán transmisiones en vivo de audio en Erasca.com/events, con repeticiones accesibles durante 90 días.
Erasca (Nasdaq: ERAS)는 RAS/MAPK 경로에 의해 유도되는 암에 중점을 둔 임상 단계의 정밀 oncology 회사로, 다가오는 세 가지 투자자 회의에 참여한다고 발표했습니다. 회사는 보스턴에서 열리는 Guggenheim Securities Healthcare Innovation Conference (11월 12일), Jefferies London Healthcare Conference (11월 20일), 그리고 코랄 게이블스에서 열리는 7th Annual Evercore HealthCONx Conference (12월 4일)에서 발표할 예정입니다. 경영진은 개별 투자자 회의에 참석하고, Erasca.com/events에서 라이브 오디오 웹캐스트를 제공하며, 90일 동안 재생이 가능합니다.
Erasca (Nasdaq: ERAS), une entreprise d'oncologie de précision en phase clinique axée sur les cancers liés à la voie RAS/MAPK, annonce sa participation à trois conférences pour investisseurs à venir. L'entreprise présentera à la Guggenheim Securities Healthcare Innovation Conference à Boston (12 novembre), à la Jefferies London Healthcare Conference (20 novembre) et à la 7th Annual Evercore HealthCONx Conference à Coral Gables (4 décembre). La direction participera à des réunions individuelles avec les investisseurs, et des webdiffusions audio en direct seront disponibles sur Erasca.com/events, avec des rediffusions accessibles pendant 90 jours.
Erasca (Nasdaq: ERAS), ein Unternehmen für präzise Onkologie in der klinischen Phase, das sich auf durch den RAS/MAPK-Weg gesteuerte Krebserkrankungen konzentriert, gibt die Teilnahme an drei bevorstehenden Investorenkonferenzen bekannt. Das Unternehmen wird auf der Guggenheim Securities Healthcare Innovation Conference in Boston (12. November), der Jefferies London Healthcare Conference (20. November) und der 7th Annual Evercore HealthCONx Conference in Coral Gables (4. Dezember) präsentieren. Das Management wird Einzelgespräche mit Investoren führen, und Live-Audio-Webcasts sind auf Erasca.com/events verfügbar, mit Rückblicken, die für 90 Tage zugänglich sind.
- None.
- None.
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.
Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)
Location: InterContinental Hotel, Boston, MA
Format: Fireside Chat
Date and Time: Tuesday, November 12, 2:00 pm Eastern Time
Jefferies London Healthcare Conference (November 19 – 21, 2024)
Location: The Waldorf Hilton, London, UK
Format: Presentation
Date and Time: Wednesday, November 20, 12:30 pm Greenwich Mean Time
7th Annual Evercore HealthCONx Conference (December 3 – 5, 2024)
Location: Loews Coral Gables Hotel, Coral Gables, FL
Format: Fireside Chat
Date and Time: Wednesday, December 4, 11:15 am Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 90 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
FAQ
When is Erasca (ERAS) presenting at the Guggenheim Securities Healthcare Conference 2024?
Where can I watch Erasca's (ERAS) investor conference presentations?
What investor conferences is Erasca (ERAS) attending in November and December 2024?
What time is Erasca's (ERAS) presentation at the Jefferies London Healthcare Conference?
